Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for AbbVie Inc. (ABBV:NYSE), powered by AI.
AbbVie Inc. is currently trading at $222.47. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for AbbVie Inc. on Alpha Lenz.
AbbVie Inc.'s P/E ratio is 93.1.
“AbbVie Inc. trades at a P/E of 93.1 (premium valuation) with strong ROE of 15367.3%. Operating margin of 32.8% indicates strong profitability.”
Ask for details →AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
“AbbVie Inc. trades at a P/E of 93.1 (premium valuation) with strong ROE of 15367.3%. Operating margin of 32.8% indicates strong profitability.”
Ask for details →AbbVie Inc. (ticker: ABBV) is a company listed on NYSE in the Healthcare sector (Drug Manufacturers - General). It has approximately 55,000 employees. Market cap is $393.3B.
The current price is $222.47 with a P/E ratio of 93.07x and P/B of -120.28x.
ROE is 15367.27% and operating margin is 32.85%. Annual revenue is $61.2B.